The FACS analysis revealed that RAD51 inhibitor treatment increased PD-L1 expression in TNBC (MDA-MB-231), lung cancer (A549), pancreatic cancer (KP-4) and colon cancer (HCT 116) cell lines in a dose-dependent manner (Figure 6A). Here, RAD51 is linked to malignant colon neoplasm.